About the Editor Gerri S. Hall, Ph.D.
|
|
- Leo Porter
- 5 years ago
- Views:
Transcription
1 About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing, and antimicrobial susceptibility testing of bacteria and fungi. Her laboratory performs clinically relevant patient care testing and research in these areas. She also teaches within the Department of Clinical Pathology as well as externally and is actively involved in teaching in the Cleveland Clinic Foundation Lerner School of Medicine of Case Western Reserve University. G.S. Hall (ed.), Interactions of Yeasts, Moulds, and Antifungal Agents: How to Detect Resistance, DOI / , Springer Science+Business Media, LLC
2 A Abelcet, 5, 6 Acremonium spp., 119 AFST. See Antifungal susceptibility testing (AFST) Agar methods, antifungal susceptibility testing on chromagar, direct testing, 79 disk diffusion, 79 E test, MIC determination vs. CLSI method, 80 gradient technique, vs. microdilution broth methods, 81 reproducible method, 80 fluconazole testing, 81 Alamar blue, colorimetric method, 76 Alternaria alternata, 118 AmBisome (LAmB), 5, 6 Amorolfine, Amphotericin absorption, 3 brand names, 1 Candida spp., clinical outcomes, distribution, 3 drug interactions, 4 5 efficacy of, 6 excretion, 3 4 formulation, 1 mechanism of action, 3 MIC interpretation, 6 pharmacodynamic target, 4 primary uses, 2 resistance, 5 6 side effects of, 4 spectrum of activity, 2 structure, 1 Anidulafungin activity, 39 adverse effects, 40 brand name/formulation, 38 Candida spp., clinical correlations, drug interactions, 40 fungal infection, treatment for, 41 interpretive criteria, 41 mechanism, MIC interpretation, 41 pharmacodynamic target, pharmacokinetics, 39 primary uses, 38 resistance, 40 Antifungal agents amorolfine, azoles imidazoles (see Imidazoles) triazoles (see Triazoles) butenafine hydrochloride, butoconazole/butoconazole nitrate, ciclopirox, dermatophytes, treatment for, 90 echinocandins anidulafungin (see Anidulafungin) caspofungin, micafungin (see Micafungin) econazole, fluorocytosine (5-FC) griseofulvin, naftifine, oxiconazole, polyenes amphotericin (see Amphotericin) Nystatin (see Nystatin) 161
3 162 Antifungal agents (cont.) potassium iodide, sertaconazole, terbinafine hydrochloride, tolnaftate, Antifungal susceptibility testing (AFST) agar method on chromagar, direct testing, 79 disk diffusion, 79 E test, MIC determinations, fluconazole testing, 81 broth microdilution method bioscreen microdilution, 78 Candida species, 76 Candifast, 77 carboxyfluorescein diacetate, 78 chloromethylfluorescein diacetate, 78 Cryptococcus species, 77 Fungites, 77 Integral System Yeast, 77 Sensititre YeastOne Colorimetric system, 76, 77 Vitek 2, 77 XTT, tetrazolium salt, 78 clinical correlations Aspergillus spp., 143, 145 Candida spp. ( see Candida spp.) Cryptococcus neoformans, 146 dimorphic fungi, organism-drug combinations, clinical utility and factors, 132 principles, rule, standardized methods, combination testing, 84 committee report on, 66 guidelines, clinical laboratory, minimum fungicidal concentration, 83 mould testing analyzing data, CLSI M38-A2, 71 endpoint determination, 72 history, macrobroth method, 72 target percent transmission readings, non-growth-based methods ergosterol assay, 82 flow cytometry, 82 molecular method, 83 patients management, 147 reference method, 76 yeast testing antibiotic medium 3, 69 break points for, 68 endpoints, 67 Etest and YeastOne panels, 71 EUCAST method, 69 history, 66 M44-A, 71 in M27-A3, 67 MIC determination, 68 RPMI 1640 medium, rule, 69 species resistance, 69, 70 turbidity, 68 ARTEMIS Global Surveillance Study, 97 Aspergillus spp. A. flavus, A. fumigatus, A. nidulans, 112 A. niger, A. terreus, 111 A. versicolor, 111 clinical correlations, AFST, 143, 145 ECVs determination for, 112 synergy and, 112 Azoles cytochrome P450 inhibition, 10 imidazoles clotrimazole (see Clotrimazole) ketoconazole (see Ketoconazole) miconazole (see Miconazole) side effects, 11 triazoles albaconazole, fluconazole, itraconazole, posaconazole, ravuconazole, voriconazole (see Voriconazole) B BioMerieux Vitek, 77 Black (Dematiaceous) fungi Alternaria spp., 118 Curvularia spp., Exophiala spp., 119 Blastomyces dermatitidis, 126 Broth microdilution method bioscreen microdilution, 78 Candida species, 76 Candifast, 77 carboxyfluorescein diacetate, 78 chloromethylfluorescein diacetate, 78
4 163 Cryptococcus species, 77 Fungites, 77 Integral System Yeast, 77 Sensititre YeastOne Colorimetric system, 76, 77 Vitek 2, 77 XTT, tetrazolium salt, 78 Butenafine hydrochloride activity, 50 brand name/formulation, 49 drug interactions, 51 mechanism, 50 MIC interpretations, 51 pharmacokinetics, 50 primary uses, resistance, 51 side effects, 50 treatment, 51 Butoconazole, C Candida spp. clinical correlations amphotericin B, echinocandins, fluconazole, flucytosine, 140 itraconazole, voriconazole, susceptibility patterns of C. albicans, 97, C. glabrata, 98 C. guilliermondii, 101 C. krusei, 100 C. lusitaniae, C. parapsilosis, 99 C. rugosa, 101 C. tropicalis, Carboxyfluorescein diacetate (CFDA), 78 Caspofungin activity, 33 brand name/formulation, 32 broth microdilution method, 78 against Candida sp., 35 Candida spp., clinical correlations, drug interactions, 34 mechanism, 33 MIC interpretations, pharmacodynamic target, 33 pharmacokinetics, 33 primary uses, 32 resistance, 34 side effects, 34 Ciclopirox, Cladophialophora carrionii, Clinical and Laboratory Standards Institute (CLSI) agar method on chromagar, direct testing, 79 disk diffusion, 79 E test, MIC determinations, fluconazole testing, 81 AST (see Antifungal) broth microdilution method bioscreen microdilution, 78 Candida species, 76 Candifast, 77 carboxyfluorescein diacetate, 78 chloromethylfluorescein diacetate, 78 Cryptococcus species, 77 Fungites, 77 Integral System Yeast, 77 Sensititre YeastOne Colorimetric system, 76, 77 Vitek 2, 77 XTT, tetrazolium salt, 78 combination testing, 84 dermatophytes (see Dermatophytes) minimum fungicidal concentration, 83 non-growth-based methods ergosterol assay, 82 flow cytometry, 82 molecular method, 83 reference method, 76 Clinical utility, antifungal susceptibility testing factors, 132 principles, rule, standardized methods, Clotrimazole activity, 12 adverse reactions, brand name/formulations, candidal infection, used for, 13 drug interactions, mechanism, 12 MIC interpretation, 13 pharmacokinetics primary uses, 12 resistance, 13 CLSI. See Clinical and Laboratory Standards Institute (CLSI) Coccidioides immitis, Cryptococcus neoformans, 146 Cryptococcus spp. clinical correlations, 146
5 164 Cryptococcus spp. (cont.) susceptibility patterns of C. gattii, 103 C. neoformans, other species, 103 Curvularia sp., 121 D Dermatophytes antifungal agents, 90 clinical manifestations, 90 CLSI reference method, keratinized tissues, humans, 89 susceptibility testing clinical applications, 94 optimal growth conditions, standardization, Dimorphic fungi clinical correlations, AFST, susceptibility testing Blastomyces dermatitidis, 126 Coccidioides immitis, Histoplasma capsulatum, Paracoccidioides brasiliensis, 127 Penicillium marneffei, 128 Sporothrix schenckii, Disk diffusion method, 79 Drug interactions amphotericin, 4 5 butenafine hydrochloride, 51 clotrimazole, echinocandins anidulafungin, 40 caspofungin, 34 micafungin, 37 5-fluorocytosine (5-FC), 10 grisefulvin, 42 imidazoles clotrimazole, ketoconazole, 16 miconazole, nystatin, 7 oral antifungal agents ( see Antifungal agents) terbinafine hydrochloride, triazoles albaconazole, 31 fluconazole, itraconazole, posaconazole, 28 ravuconazole, voriconazole, 24 E Echinocandins anidulafungin (see Anidulafungin) Candida spp., clinical outcomes bloodstream infection isolates, 142 data analysis, ECVs, 143 MIC interpretive breakpoints, 143, 145 pharmacodynamics, 142 and in vitro resistance, 143, 144 caspofungin (see Caspofungin) micafungin activity, 36 brand name/formulation, 35 drug interactions, 37 esophageal candidiasis, 38 hypersensitivity reactions, mechanism, 35 MIC interpretation, 38 pharmacodynamic target, 36 pharmacokinetics, 36 primary uses, 35 resistance, 37 side effects, 37 Econazole, Epidemiological cutoff values (ECVs), 112 Epidermophyton, 90 Ergosterol assay, 82 E test, antifungal susceptibility testing vs. CLSI method, 80 gradient technique, vs. microdilution broth methods, 81 reproducible method, 80 European Community on Antifungal Susceptibility Testing (EUCAST), 69 Exophiala spp., 119 F 5-FC. See 5-Fluorocytosine (5-FC) FDA. See Food and Drug Administration (FDA) Flow cytometry, 82 Fluconazole activity, 17 agar-based methods, 81 brand name/formulations, 17 Candida spp., clinical correlations CLSI interpretations, 134 dose/mic ratio relationship, MIC, low and high levels of, 135 MIC ranges, analysis of,
6 165 mucosal and invasive infections, S-DD range, 135 drug interactions, mechanism, 18 MIC interpretation, 19 pharmacodynamic target, 18 pharmacokinetics, 18 primary uses, 17 resistance, 19 side effects, yeast, 19 Flucytosine Candida spp. and, fluorocytosine, 9 5-Fluorocytosine (5-FC) absorption, 9 brand names, 8 distribution, 9 drug interactions, 10 excretion, 9 formulation, 8 mechanism, 9 MIC interpretation, 10 pharmacodynamic target, 9 primary uses, 8 resistance, 10 side effects, 9 10 spectrum of activity, 8 structure, 8 Fonsecaea pedrosoi, 122 Food and Drug Administration (FDA), 90 Fungus Testing Laboratory, 120 Fusarium spp., antifungal susceptibility testing, G Grisefulvin activity, 42 brand names/formulation, 41 mechanism, 42 MIC interpretation, 42 pharmacokinetics, 42 primary uses, 41 resistance, 42 side effects/drug interactions, 42 tinea capitis, 43 H Histoplasma capsulatum, I Imidazoles clotrimazole, ketoconazole, miconazole, Itraconazole absorption, activity, 20 adverse reactions, brand names/formulation, 20 Candida spp., clinical correlations, distribution, 21 drug interactions, excretion, 21 mechanism of action, 20 MIC interpretation, 22 mould, 22 pharmacodynamic target, 21 primary uses, 20 resistance, 22 K Ketoconazole activity, 15 adverse reactions, 16 brand name/formulations, 15 dermatophyte infections, treatment of, 17 drug interactions, 16 mechanism, 16 MIC interpretations, 17 pharmacokinetics, 16 primary uses, 15 resistance, 16 Kirby-Bauer method, 71 M MBC. See Minimum bactericidal concentration Mentax cream, Methylene blue-glucose, 71 MFC. See Minimum fungicidal concentration MIC. See Minimum inhibitory concentration Micafungin activity, 36 brand name/formulation, 35 Candida spp., clinical correlations, drug interactions, 37
7 166 Micafungin (cont.) esophageal candidiasis, 38 hypersensitivity reactions, mechanism, 35 MIC interpretation, 38 pharmacodynamic target, 36 pharmacokinetics, 36 primary uses, 35 resistance, 37 side effects, 37 Miconazole activity, 14 brand name/formulation, 13 dosage of, 15 mechanism, 14 MIC interpretations, 15 pharmacokinetics, 14 primary uses, 14 resistance, side effects, 14 Microsporum, 90 Minimum bactericidal concentration (MBC), 83 Minimum effective concentration (MEC), antifungal activity, 35, 38, 67, 141 Minimum fungicidal concentration (MFC), 50, 83 Minimum inhibitory concentration (MIC), 66, 91 amphotericin, 6 anidulafungin, 41 butenafine hydrochloride, 51 caspofungin, clotrimazole, 13 distribution, 142 and dose ratio relationship, 136 echinocandins, interpretive breakpoints, fluorocytosine, 10 grisefulvin, 42 itraconazole, 22 micafungin, 38 miconazole, 15 nystatin, 7 terbinafine hydrochloride, 45 voriconazole, 25 Mould testing analyzing data, CLSI M38-A2, 71 endpoint determination, 72 history, macrobroth method, 72 target percent transmission readings, Mueller-Hinton agar, 71 N Naftifine, National Committee of Clinical Laboratory Standards (NCCLS), 75 Neo-Sensitabs tablets, 79 Nystatin brand names, 6 drug interactions, 7 formulation, 6 liposomal formulation, 8 mechanism, 7 MIC interpretation, 7 pharmacokinetics, 7 primary uses, 6 resistance, 7 side effects of, 7 spectrum of activity, 6 7 O Oxiconazole activity, 59 adverse reaction, 59 brand name/formulation, 58 drug interactions, 59 fungal infection, treatment for, 60 mechanism of action, 59 MIC interpretation, 59 primary uses, 59 P Paecilomyces spp., Paracoccidioides brasiliensis, 127 Penicillium marneffei, 128 Penicillium spp., 116 Phialophora verrucosa, 119 Potassium iodide adverse reaction, 61 brand name/formulation, 60 drug interactions, 61 mechanism of action, 60 pharmacokinetics, primary uses, 60 sporotrichosis, treatment for, 61 Pseudallescheria boydii, 117 Q Quality control ranges, antifungal agents, 93
8 167 R Ravuconazole, Resistance. See specific Antifungal agents Rhizopus oryzae, antifungal susceptibility testing, 119 Rhodotorula spp., Rifabutin, 11, 24, 28 Rifampin, 11, 34 RPMI 1640 medium, 91 S Sabouraud dextrose broth, 91 Saccharomyces cerevisiae, 105 Scedosporium S. apiospermum, S. prolificans, 114 Scopulariopsis brevicaulis, S-DD. See Susceptible dose-dependent Senititre YeastOne colorimetric method broth microdilution method, 76 S. apiospermum, 114 SENTRY study, 98 Sertaconazole, antifungal agents, Sporothrix schenckii, Susceptibility patterns black (dematiaceous) fungi Alternaria spp., 118 Curvularia spp., Exophiala spp., 119 combination testing, antifungal agents, 122 hyaline moulds Acremonium spp., 117 Aspergillus spp. ( see Aspergillus spp.) Fusarium spp., Paecilomyces spp., Penicillium spp., 116 Scedosporium spp., Scopulariopsis spp., yeasts Candida spp. ( see Candida spp.) Cryptococcus spp. ( see Cryptococcus spp.) Rhodotorula spp., Saccharomyces cerevisiae, 104 Trichosporon spp., 104 Zygomycetes Myocladus corymbifereus, 117 Rhizopus oryzae, 117 Rhizopus spp., 118 Saksenaea spp., 118 Susceptibility testing antifungal susceptibility testing ( see Antifungal susceptibility testing (AFST)) dermatophytes antifungal agents, 90 clinical manifestations, 90 CLSI reference method, keratinized tissues, humans, 89 susceptibility testing clinical applications, 94 optimal growth conditions, standardization, dimorphic fungi Blastomyces dermatitidis, 126 Coccidioides immitis, Histoplasma capsulatum, Paracoccidioides brasiliensis, 127 Penicillium marneffei, 128 Sporothrix schenckii, Susceptible dose-dependent (S-DD), 134 T Terbinafine hydrochloride activity, 43 brand name/formulation, 43 drug interactions, mechanism, 43 MIC interpretations, 45 nail infection, treatment for, 45 pharmacokinetics absorption, distribution, 44 excretion, 44 primary uses, 43 resistance, 45 side effects, 44 Tolnaftate, Triazoles albaconazole, fluconazole, itraconazole, posaconazole, ravuconazole, voriconazole (see Voriconazole) Trichophyton species, 91 Trichosporon spp., 104 V Voriconazole absorption, 23
9 168 Voriconazole (cont.) activity, 23 adverse effects, 25 brand name/formulation, 22 Candida spp., clinical correlations analysis of, 139 breakpoints, efficacy of, h MIC, CLSI and EUCAST methods, 139, 140 investigator assessment vs. MIC, S-DD category, 139 distribution, 23 drug interactions, 24 excretion, mechanism, 23 MIC interpretation, 25 pharmacodynamic target, 24 primary uses, resistance, 25 side effects, 24 Zygomycetes infection, 26 Y Yeast, antifungal susceptibility testing of antibiotic medium 3, 69 break points for, 68 CLSI M27-A3, 67 endpoints, 67, 68 Etest and YeastOne panels, 71 EUCAST method, 69 history, 66 M44-A, 71 MIC determination, 68 RPMI 1640 medium, rule, 69 species resistance, 69, 70 turbidity, 68 Yeast nitrogen base (YNB) medium, 91 Z Zygomycetes Myocladus corymbifereus, 117 Rhizopus oryzae, 117 Rhizopus spp., 118 Saksenaea spp., 118
ANTIMYCOTIC DRUGS Modes of Action
ANTIMYCOTIC DRUGS Modes of Action Prapasarakul Nuvee, D.V.M., Ph.D. Department of Veterinary Microbiology, Faculty of Veterinary Science, Chulalongkorn University 1 What drugs act as antifungal agents?
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationFungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell
Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate
More informationNew triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
For reprint orders, please contact reprints@expert-reviews.com New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance Expert Rev. Anti Infect. Ther. 7(8), 981 998
More informationTreatment of rare and emerging fungal infections. EFISG Educational Workshop 15 th ECCMID April 2, 2005, Copenhagen
Treatment of rare and emerging fungal infections EFISG Educational Workshop 15 th ECCMID April 2, 2005, Copenhagen Helen Sambatakou Lecturer in Medicine and Infectious Diseases, University of Athens, Greece
More informationUpdate zu EUCAST 2012 Cornelia Lass-Flörl
Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationyour lab focus susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal testing.
626 CE update [microbiology and virology] Antifungal Susceptibility Methods and Their Potential Clinical Relevance Ana Espinel-Ingroff, PhD Medical College of Virginia, Virginia Commonwealth University,
More informationCourse content. Chemotherapeutic agents
Course content 1 Chemotherapeutic agents Mechanism of actions Indications Contraindications/Cautions Drug interactions Side-effects/Adverse reactions Dosage regimen (occasionally) Reference Books 2 Pharmacology
More informationAntifungal drugs Dr. Raz Muhammed
Antifungal drugs 13. 12. 2018 Dr. Raz Muhammed 2. Flucytosine (5-FC) Is fungistatic Is a synthetic pyrimidine antimetabolite Is often used in combination with amphotericin B in the treatment of systemic
More informationReview. Ana Espinel-Ingroff
Review Rev Iberoam Micol 2003; 20: 121-136 121 In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationAntifungal therapies differences in agents
Antifungal therapies differences in agents The basic Fungi are eukaryotes Eukaryote = an organism whose cells contain complex structures enclosed within membrane. Most Common Fungal Pathogens Dermatophytes
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationIn Vitro Studies with R 51,211 (Itraconazole)
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1984, p. 5-9 Vol. 26, No. 1 0066-4804/84/070005-05$02.00/0 Copyright 1984, American Society for Microbiology In Vitro Studies with R 51,211 (Itraconazole) ANA
More informationSUSCEPTIBILITY PROFILE OF EMERGING FUNGAL PATHOGENS
SUSCEPTIBILITY PROFILE OF EMERGING FUNGAL PATHOGENS Professor Lia Monica JUNIE, Department of Microbiology, University of Medicine and Pharmacy, Cluj Napoca, Romania The most common fungal pathogens are:
More informationAUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA : PART 2 THE MOULDS ASPERGILLUS, SCEDOSPORIUM AND FUSARIUM.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 00-0: PART THE MOULDS ASPERGILLUS, SCEDOSPORIUM AND FUSARIUM. AUSTRALIAN Sarah Kidd, Rose Handke and ANTIFUNGAL David Ellis SUSCEPTIBILITY DATA 00-00 David SA
More informationFungal Infection Pre-Infusion Data
Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode
More informationAntifungal Agents. Polyenes Azoles Allyl and Benzyl Amines Other antifungals
OPTO 6434 General Pharmacology Antifungal Agents Dr. Alison McDermott Room 254 HBSB, Phone 713-743 1974 Email amcdermott@optometry.uh.edu Fall 2015 Reading: Chapter 50 Brody s Human Pharmacology by Wecker
More informationReceived 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationTEPZZ Z9Z74_A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION
(19) TEPZZ Z9Z74_A_T (11) EP 3 090 741 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 09.11.2016 Bulletin 2016/4 (21) Application number: 1642039.1 (1) Int Cl.: A61K 31/203 (2006.01) A61K
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationAna Espinel-Ingroff 1, Elizabeth Johnson 2, Hans Hockey 3 and Peter Troke 4 *
Journal of Antimicrobial Chemotherapy (2008) 61, 616 620 doi:10.1093/jac/dkm518 Advance Access publication 25 January 2008 Activities of voriconazole, itraconazole and amphotericin B in vitro against 590
More informationEUCAST-AFST Available breakpoints 2012
EUCAST-AFST Available breakpoints th NSMM meeting Göteborg, Sweden October th EUCAST-AFST documents Reference Methods Yeast E.DEF. () TN- E.DEF. (CMI epub July) E.DEF. () TN- E.DEF. () Breakpoints Compound
More informationFOCUS. Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2001, p. 643 658 Vol. 14, No. 4 0893-8512/01/$04.00 0 DOI: 10.1128/CMR.14.4.643 658.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. FOCUS
More informationC. albicans C. tropicalis C. parapsilosis C. kefyr C. glabrata C. krusei C. guillermondii C. lusitaniae THERAPY USING ANTIFUNGALS AND ANTIVIRALS
THERAPY USING ANTIFUNGALS AND ANTIVIRALS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu CLASSIFICATION OF FUNGI Yeasts Candida Cryptococcus
More informationReceived 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationAntifungal Drugs 35 I. OVERVIEW II. DRUGS FOR SUBCUTANEOUS AND SYSTEMIC MYCOTIC INFECTIONS
Antifungal Drugs 35 I. OVERVIEW Infectious diseases caused by fungi are called mycoses, and they are often chronic in nature. 1 Some mycotic infections are superficial and some involve the skin (cutaneous
More informationAntifungal resistance mechanisms in pathogenic fungi
Antifungal resistance mechanisms in pathogenic fungi Shivaprakash M Rudramurthy Additional Professor, Mycology Division Center of Advanced Research in Medical Mycology, National Culture Collection of Pathogenic
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More informationJapan Antifungal Surveillance Program (1):
183 Japan Antifungal Surveillance Program (1): 2001 2002 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 16 9 14 16 10 12 2001 6 2002 3 2 11 576 fluconazole (FLCZ),
More informationMycology Review. Background. Background. Specimen Collection. Calcofluor White. Methods. Yeasts. Moulds. Melissa B. Miller, Ph.D.
Background Mycology Review Melissa B. Miller, Ph.D. April 4, 2008 Yeasts Unicellular Divide by budding or binary fission Moulds Filamentous hyphae interweave to form mycelium Saprobic phase: airborne,
More informationA class IIa medical device intended for mild-to-moderate fungal nail infection PRODUCT MONOGRAPH
A class IIa medical device intended for mild-to-moderate fungal nail infection PRODUCT MONOGRAPH AWB-2052628721 Date of Preparation March 2017 Introduction to Bayer Bayer is a Life Science company with
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationFungal Infection Post-Infusion Data
Fungal Infection Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / Visit: 100 day 6 months 1 year 2 years >2 years. Specify: CIBMTR Form 2146 revision
More informationReceived 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 70 75 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.01551-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Use of Fluconazole
More informationAli Alabbadi. Sarah Jaar ... Nader
24 Ali Alabbadi Sarah Jaar... Nader Intro to Mycology *underlined text was explained in the lecture but is not found in the slides -mycology: the study of the mycoses of man (fungal infections) -less than
More informationManagement of fungal infection
Management of fungal infection HKDU symposium 17 th May 2015 Speaker: Dr. Thomas Chan MBBS (Hons), MRCP, FHKCP, FHKAM Synopsis Infection caused by fungus mycoses Skin infection by fungus is common in general
More informationNew antifungal agents
New antifungal agents Dr Atul Patel, MD, FIDSA Chief Consultant and Director Infectious Diseases Clinic Vedanta Institute of Medical Sciences Ahmedabad, India Presented at MMTN Malaysia Conference 5 6
More informationEchinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden
JOURNAL OF CLINICAL MICROBIOLOGY, July 2011, p. 2516 2521 Vol. 49, No. 7 0095-1137/11/$12.00 doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationANA ESPINEL-INGROFF* Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 198 202 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activity of the New Triazole Voriconazole (UK-109,496)
More informationAntifungals and Anti-Tuberculosis Agents
Antifungals and Anti-Tuberculosis Agents Christine Kubin, Pharm.D.,., BCP Clinical Pharmacist, Infectious Diseases NewYork-Presbyterian Hospital Columbia University Medical Center Antifungal Agents 1 Fungi
More informationTHE TREATMENT OF MYCOSES IN REPTILES: A REVIEW OF ANTIFUNGAL DRUGS
THE TREATMENT OF MYCOSES IN REPTILES: A REVIEW OF ANTIFUNGAL DRUGS Jean A. Paré, DMV, DVSc, Dipl ACZM Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, 2015 Linden
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationInterpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2006, p. 435 447 Vol. 19, No. 2 0893-8512/06/$08.00 0 doi:10.1128/cmr.19.2.435 447.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Interpretive
More informationReceived 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 858 864 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01900-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Correlation
More informationComparative In Vitro Antifungal Activity of Amphotericin B and Amphotericin B Methyl Ester
ANTIMICROBiAL AGENTS AND CHEMOTHERAY, Jan. 975, P. 58-63 Copyright 0 975 American Society for Microbiology Vol. 7, No. Printed in U.S.A. Comparative In Vitro Antifungal Activity of Amphotericin B and Amphotericin
More information(Notes on Anti-TB agents are included in the TB syllabus)
(Notes on Anti-TB agents are included in the TB syllabus) Antifungal Agents A. Zuger MD General background: 1. Fungi are eukaryotes, with more cellular similarities to human cells than to bacterial cells.
More informationIsavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
REVIEWS OF ANTI-INFECTIVE AGENTS INVITED ARTICLE Louis D. Saravolatz, Section Editor Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent Marisa H. Miceli 1 and Carol A. Kauffman 1,2 1 Division
More informationMedical Mycology. Dr. Hala Al Daghistani
Medical Mycology Dr. Hala Al Daghistani Mycotic Infections GENERAL CONCEPTS A. The fungi represent a diverse, heterogeneous group of eukaryotic B. Most of these organisms are plant pathogens and relatively
More informationand are categorized into two groups: superficial and systemic. Superficial yeast infections can affect different parts of the human body
Introduction / 1 Yeasts are unicellular fungi that cause a wide range of infections and are categorized into two groups: superficial and systemic. Superficial yeast infections can affect different parts
More informationFungal update. Liise-anne Pirofski, M.D. Albert Einstein College of Medicine
Liise-anne Pirofski, M.D. Albert Einstein College of Medicine Fungal update http://clicks.robertgenn.com/miss-potter.php http://letterfromhere.blogspot.com/2007/06/beatrix-potters-jog-trot-through.html
More informationPharmaceutical Chemistry II. Antifungal Agents. = Antimycotics. Tutorial 1
Pharmaceutical Chemistry II Antifungal Agents = Antimycotics Tutorial 1 1) Give examples of some common fungal infections indicating whether they are rather superficial or systemic. Fungal infections Tinea
More informationAntimycotics. November 14, Jan Strojil. Ústav farmakologie LF UP
Ústav farmakologie LF UP November 14, 2005 Introduction Polyens Azoles Alylamines Other Outline Introduction Polyens Azoles Alylamines and morfolines Other Introduction Polyens Azoles Alylamines Other
More informationUpdated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017
Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline
More informationon November 3, 2018 by guest
JOURNAL OF CLINICAL MICROBIOLOGY, June 2007, p. 1811 1820 Vol. 45, No. 6 0095-1137/07/$08.00 0 doi:10.1128/jcm.00134-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationMed Chem 401: Mycology (www.doctorfungus.org) Mycology
Med Chem 401: Mycology (www.doctorfungus.org) Mycology is the Study of Fungi (Monera, Protoctista, Fungi, Plantae, Animalia). Fungi are eukaryotic cells and as such contain nuclei, mitochondria, ER, golgi,
More informationAntifungal Agents. Prof. Suheil Zmeili Faculty of Medicine Department of Pharmacology University of Jordan
Antifungal Agents Prof. Suheil Zmeili Faculty of Medicine Department of Pharmacology University of Jordan Antifungal Agents Objectives: - Know Available antifungal drugs - Know their MOA - Know their Pharmacokinetic
More informationImproving Clinical Outcomes in Fungal Infection Control and Management
Improving Clinical Outcomes in Fungal Infection Control and Management DISCLAIMER The information within this CME/CE activity is for continuing education purposes only, and is not intended to substitute
More informationIt is well known that patient populations at risk for serious. Voriconazole: A New Triazole Antifungal Agent. Formulary Forum
Formulary Forum Voriconazole: A New Triazole Antifungal Agent Margaret M Pearson, P David Rogers, John D Cleary, and Stanley W Chapman OBJECTIVE: To review the pharmacology, in vitro susceptibility, pharmacokinetics,
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationThis insert contains prescribing information only. For more comprehensive Information, a professional brochure is available upon request.
This insert contains prescribing information only. For more comprehensive Information, a professional brochure is available upon request. POSACONAZOLE NOXAFIL* 40 mg/ml Oral Suspension Antifungal Rx Schering-Plough
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationThe Differentiation of Yeast and Yeast-Like Forms in Human Tissues. Introduction. Histochemical Stains Used to Detect Fungi. Histopathologic Diagnoses
The Differentiation of Yeast and Yeast-Like Forms in Human Tissues Gary W. Procop, MD Chair, Clinical Pathology Staff, Anatomic Pathology Director, Molecular Microbiology, Mycology, and Parasitology Cleveland
More informationEchinocandin Antifungal Drugs in Fungal Infections
REVIEW ARTICLE Drugs 2011; 71 (1): 11-41 0012-6667/11/0001-0011/$55.55/0 ª 2011 Adis Data Information BV. All rights reserved. Echinocandin Antifungal Drugs in Fungal Infections A Comparison Sharon C.-A.
More informationReceived 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1396 1400 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01512-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More informationComparison of in vitro antifungal activities of efinaconazole and. currently available antifungal agents against a variety of pathogenic
AAC Accepts, published online ahead of print on 14 January 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02056-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Comparison
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationFungi. Eucaryotic Rigid cell wall(chitin, glucan) Cell membrane ergosterol Unicellular, multicellular Classic fungus taxonomy:
MYCOLOGY Mycology I Fungi Eucaryotic Rigid cell wall(chitin, glucan) Cell membrane ergosterol Unicellular, multicellular Classic fungus taxonomy: Morphology Spore formation FFungi Yeast Mold Yeastlike
More informationUpdates and practical guide on antifungal agents
Updates and practical guide on antifungal agents Dr Atul Patel, MD, FIDSA Chief Consultant and Director Infectious Diseases Clinic Vedanta Institute of Medical Sciences Ahmedabad, India Presented at MMTN
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationFungal infections and critically ill adults
Martin Beed FRCA FFICM DM Richard Sherman MRCP FRCA FFICM Stephen Holden MSc FRCPath 1A02,2C03 Key points The incidence of fungal diseases in critically ill patients is thought to be increasing, most commonly
More information1. Multiple choice (30 2 each); circle the number of the correct choice. b. Trichophyton schoenleinii is traditionally most associated with
NAME SS# EXAM 2 March 26, 2002 BIO 329 Directions: All explanations, definitions, and descriptions should be presented in good English This means complete sentences should be used except when lists or
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationMycology. Dr. Agoston Ghidan
Mycology Dr. Agoston Ghidan 27.10.2014. Fungi are eukaryotic cells each fungal cell has: nucleus and nuclear membrane endoplasmic reticulum mitochondria most fungi are obligate or facultative aerobes most
More informationREVIEW. Changing epidemiology of systemic fungal infections M. Richardson 1 and C. Lass-Flörl 2
REVIEW Changing epidemiology of systemic fungal infections M. Richardson 1 and C. Lass-Flörl 2 1 Department of Bacteriology &Immunology, University of Helsinki, and Helsinki University Central Hospital
More informationTrichophyton Microsporum Epidermophyton. dermatomycosis. Dematiaceous(pigmented fungi ) Dimorphic fungi Yeast and yeast like saprophyte
Cutaneous candidiasis dermatophytosis Trichophyton Microsporum Epidermophyton dermatomycosis Dematiaceous(pigmented fungi ) Dimorphic fungi Yeast and yeast like saprophyte dermatomycosis Yeast & yeast
More informationNational Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention Invasive Candidiasis
More information9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Invasive Candidiasis Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention
More informationAntifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationClinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
CLINICAL MICROBIOLOGY REVIEWS, Apr. 1998, p. 382 402 Vol. 11, No. 2 0893-8512/98/$04.00 0 Copyright 1998, American Society for Microbiology Clinical, Cellular, and Molecular Factors That Contribute to
More informationMedical Mycology. Dr. Hala Al Daghistani
Medical Mycology Dr. Hala Al Daghistani FAre eukaryotes that grow in two basic forms, a yeasts and molds (or moulds). Growth in the mold form occurs by production of multicellular filamentous colonies.
More informationUpdate on Candida Infection Nov. 2010
Update on Candida Infection Nov. 2010 Gary Wong Pharmacy Clinical site leader University Health Network Course coordinator University of Toronto Goals What is an yeast infection Risk factors for yeast
More informationProduct Information NOXAFIL (posaconazole) MODIFIED RELEASE 100 mg TABLETS and 40 mg/ml ORAL SUSPENSION
Product Information NOXAFIL (posaconazole) MODIFIED RELEASE 100 mg TABLETS and 40 mg/ml ORAL SUSPENSION NAME OF THE MEDICINE Posaconazole. Posaconazole is a broad spectrum triazole antifungal compound
More informationTherapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
Journal of Antimicrobial Chemotherapy Advance Access published December 29, 2013 J Antimicrob Chemother doi:10.1093/jac/dkt508 Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the
More informationCorrelation of culture with histopathology in fungal burn wound colonization and infection
burns 33 (2007) 341 346 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/burns Correlation of culture with histopathology in fungal burn wound colonization and infection Christina
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATINS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationANTIFUNGAL DRUG DISCOVERY: FOCUS ON INCRUSTOPORIN DERIVATIVES
Charles University in Prague Faculty of Pharmacy in Hradec Králové ATIFUGAL DRUG DISCOVERY: FOCUS O ICRUSTOPORI DERIVATIVES Dissertation thesis Luís André Vale Silva Hradec Králové 2006 - 2 - As a society,
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationBiochemical Targets for Antifungal Chemotherapy
Biochemical Targets for Antifungal Chemotherapy Fungal cells are complex organisms that share many biochemical targets with other eukaryotic cells. Therefore, agents that interact with fungal targets not
More information